share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%), etc.

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%), etc.

Avalo Therapeutics | SC 13G：超過5%持股股東披露文件-Deep Track Capital, LP(9.99%),Deep Track Biotechnology Master Fund, Ltd.(9.99%)等
SEC announcement ·  04/05 16:04
Moomoo AI 已提取核心訊息
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, have filed a Schedule 13G with the United States Securities and Exchange Commission on April 5, 2024, indicating a shared voting and dispositive power over 114,775 shares of Avalo Therapeutics, Inc. This represents 9.99% of the company's class of common stock. The filing, which is required due to the acquisition of shares that meet the threshold for reporting, states that the shares include 1,940.68125 Series C Non-Voting preferred stock and 1,164,408 warrants, both subject to a beneficial ownership limitation of 9.99%. The filing asserts that the securities were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics, Inc. and were not held in connection with any transaction having that purpose or effect. The principal business offices of the reporting persons are located in Delaware, the Cayman Islands, and the United States, respectively.
Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin於2024年4月5日向美國證券交易委員會提交了附表13G，表示對Avalo Therapeutics, Inc.的114,775股股票擁有共同投票權和處置權。這佔該公司普通股類別的9.99％。由於要收購符合申報門檻的股份，該文件是必需的。該文件指出，這些股票包括1,940.68125股C系列無表決權優先股和1,164,408份認股權證，均受益所有權上限爲9.99％。該文件稱，收購這些證券不是爲了改變或影響Avalo Therapeutics, Inc.的控制權，也不是與任何具有該目的或效果的交易有關而持有的。申報人的主要業務辦公室分別位於特拉華州、開曼群島和美國。
Deep Track Capital, LP以及Deep Track Biotechnology Master Fund, Ltd.和David Kroin於2024年4月5日向美國證券交易委員會提交了附表13G，表示對Avalo Therapeutics, Inc.的114,775股股票擁有共同投票權和處置權。這佔該公司普通股類別的9.99％。由於要收購符合申報門檻的股份，該文件是必需的。該文件指出，這些股票包括1,940.68125股C系列無表決權優先股和1,164,408份認股權證，均受益所有權上限爲9.99％。該文件稱，收購這些證券不是爲了改變或影響Avalo Therapeutics, Inc.的控制權，也不是與任何具有該目的或效果的交易有關而持有的。申報人的主要業務辦公室分別位於特拉華州、開曼群島和美國。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息